摘要
由于PET在心肌灌注显像方面具有高分辨率、高灵敏度、低组织衰减和心肌血流定量等优势而使得PET心肌灌注显像剂的研究日益受到关注。本文介绍了目前已经应用于临床的PET心肌灌注显像剂的情况,分别综述了18F标记和其他正电子核素标记的PET心肌灌注显像剂的研究进展,重点讨论了几种亲脂性阳离子类和线粒体复合物Ⅰ(MC-Ⅰ)抑制剂类18F标记心肌灌注显像剂,特别是近年取得突破性进展的MC-Ⅰ抑制剂类心肌灌注显像剂(如BMS-747158-02和[18F]FP1OP),介绍了各类PET心肌灌注显像剂的生物性能、心肌摄取机制,对其优缺点进行比较,并对PET心肌灌注显像剂的应用前景进行了展望。
Positron emission tomography （PET） provides certain advantages on myocardial perfusion imaging, such as higher resolution, greater sensitivity, lower tissue attenuation, and absolute quantification of myocardial blood flow, etc. Therefore the research on PET myocardial perfusion imaging agents has caused great concern recently. The current PET agents for myocardial perfusion used in clinic are introduced and commented. The advances in^18F and other positron nuclides labeled PET myocardial perfusion imaging agents are reviewed analogues of MC-I inhibitors, such as BMS-747158-02 and [ ^18F] FP1OP, which have been made breakthrough progress recently. The biological properties and myocardial uptake mechanism of PET myocardial perfusion imaging agents are also introduced, and their advantages and disadvantages are compared. The trend for developing PET myocardial perfusion imaging agents is proposed in this paper as well.
出处
《化学进展》
SCIE
CAS
CSCD
北大核心
2012年第10期1966-1973,共8页
Progress in Chemistry
基金
国家自然科学基金项目(No.20871020)
北京市自然科学基金项目(No.2092018)
中央高校基本科研业务费专项资金资助
